|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 23:15
|
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures (The Newswire)
|
|
|
Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures of the Company (each, a “Convertible Debenture”). The Company issued 3,673 Convertible Debentures for aggregate gross proceeds of C$3,673,000 pursuant to the Offering.
The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement (the “Maturity Date”). Each Convertible Debenture will bear interest at 25.00% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the Maturity Date, the outstanding principal amount of the Convertible Deben...
|
|
|
03.06.26 - 22:33
|
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire EN)
|
|
|
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET....
|
|
|
03.06.26 - 22:33
|
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET....
|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 21:42
|
Corporate News: Amgen (EQS)
|
|
|
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM...
|
|
|
|
|
|
|
|
|
03.06.26 - 21:18
|
ME Therapeutics Announces Private Placement (Business Wire)
|
|
|
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICESVANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share') and one non-transferrable common share purchase warrant (a “Warrant”), with each Warrant being exercisable into one additional Share at an exercise price of $2.00 each for three years from the date of issuance, subject to an acceleration clause whereby, if the volume weighted average price of the Shares is at or above $3.00 for ten consecutive trading days, the Company may accelerat...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
